Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Psychedelics Business

Braxia Health Becomes First Ketamine Therapy Provider in Quebec
05/14/2021
Braxia Scientific, a Canadian operator of outpatient psychedelic research and treatment facilities, announced it has entered into a joint venture with Neurotherapy Montreal to open the first ketamine therapy clinic in Quebec.
Braxia Scientific, a Canadian operator of outpatient psychedelic research and treatment facilities, announced it has entered into a joint venture with Neurotherapy Montreal to open the first ketamine therapy clinic in Quebec.
Braxia Scientific, a Canadian...
05/14/2021
Behavioral Healthcare Executive
Novamind Adding 4 Psychedelic Mental Health Clinics, Doubling Size of Network
05/04/2021
Novamind, a mental health company that specializes in psychedelic medicine, has announced plans to open 4 new Cedar Psychiatry clinics in Utah, which will double its network to 8 locations in the state overall. Construction has begun on...
Novamind, a mental health company that specializes in psychedelic medicine, has announced plans to open 4 new Cedar Psychiatry clinics in Utah, which will double its network to 8 locations in the state overall. Construction has begun on...
Novamind, a mental health...
05/04/2021
Behavioral Healthcare Executive
Field Trip Health Opens Houston Center, Plans 5 More Facilities
05/04/2021
Psychedelic therapy provider Field Trip Health on Tuesday announced the opening of its fifth U.S. location, along with plans to build five more locations. The newly opened location is in the River Oaks District of Houston and is Field Trip’s...
Psychedelic therapy provider Field Trip Health on Tuesday announced the opening of its fifth U.S. location, along with plans to build five more locations. The newly opened location is in the River Oaks District of Houston and is Field Trip’s...
Psychedelic therapy provider...
05/04/2021
Behavioral Healthcare Executive
MindMed Begins Trading on Nasdaq
04/28/2021
MindMed, a psychedelic medicine biotech firm, is now on the Nasdaq Capital Market. Trading of MindMed shares began on Tuesday under the symbol “MNMD.” The company also trades on the Canadian exchange NEO (symbol: MMED) and in Germany...
MindMed, a psychedelic medicine biotech firm, is now on the Nasdaq Capital Market. Trading of MindMed shares began on Tuesday under the symbol “MNMD.” The company also trades on the Canadian exchange NEO (symbol: MMED) and in Germany...
MindMed, a psychedelic medicine...
04/28/2021
Behavioral Healthcare Executive
Adoption of Psychedelic-Assisted Therapy Shows Path for Other Practices
Adoption of Psychedelic-Assisted Therapy Shows Path for Other Practices
04/12/2021
We should study psychedelic-assisted therapy apart from its potential clinical value. It offers important lessons on the adoption of healthcare practices. Scientific progress often follows a circuitous path, but the journey taken by this...
We should study psychedelic-assisted therapy apart from its potential clinical value. It offers important lessons on the adoption of healthcare practices. Scientific progress often follows a circuitous path, but the journey taken by this...
We should study...
04/12/2021
Behavioral Healthcare Executive
News
Mass General Opens Center to Study Psychedelics in Treatment of Mental Illness
03/15/2021
Massachusetts General Hospital recently announced the opening of a new program to study the use of psychedelics to treat mental illnesses, including depression, anxiety and PTSD.
Massachusetts General Hospital recently announced the opening of a new program to study the use of psychedelics to treat mental illnesses, including depression, anxiety and PTSD.
Massachusetts General Hospital...
03/15/2021
Behavioral Healthcare Executive
Aion Therapeutic Opens International Center in Jamaica
03/04/2021
Aion Therapeutic has announced the opening of the Aion International Center for Psychedelic Psychiatry, a Jamaica-based facility that will specialize in the use of psilocybin in treating addiction, depression, major depressive disorder, and...
Aion Therapeutic has announced the opening of the Aion International Center for Psychedelic Psychiatry, a Jamaica-based facility that will specialize in the use of psilocybin in treating addiction, depression, major depressive disorder, and...
Aion Therapeutic has announced...
03/04/2021
Behavioral Healthcare Executive
atai Life Sciences Announces Close of $157 Million Financing Round
03/03/2021
atai Life Sciences, a biopharmaceutical firm developing psychedelic and non-psychedelic compounds for mental health disorders, announced on Wednesday that it has closed a $157 million Series D round of financing. The company has been valued...
atai Life Sciences, a biopharmaceutical firm developing psychedelic and non-psychedelic compounds for mental health disorders, announced on Wednesday that it has closed a $157 million Series D round of financing. The company has been valued...
atai Life Sciences, a...
03/03/2021
Behavioral Healthcare Executive
ATMA Opens Psychedelic Therapy Facility in Calgary
02/22/2021
ATMA Journey Centers this month has opened the first non-ketamine psychedelic therapy clinic in Canada. The Alberta-based company announced the opening of ATMA Calgary Urban Journey Clinic, a 5,000-square-foot facility in central Calgary...
ATMA Journey Centers this month has opened the first non-ketamine psychedelic therapy clinic in Canada. The Alberta-based company announced the opening of ATMA Calgary Urban Journey Clinic, a 5,000-square-foot facility in central Calgary...
ATMA Journey Centers this month...
02/22/2021
Behavioral Healthcare Executive
News
Field Trip Opens Treatment Center in Atlanta
01/27/2021
Field Trip Health this week announced the opening of a new location in Atlanta. The facility joins Field Trip’s other U.S. sites in New York, Los Angeles and Chicago, and it is the first of several new treatment centers the company plans to...
Field Trip Health this week announced the opening of a new location in Atlanta. The facility joins Field Trip’s other U.S. sites in New York, Los Angeles and Chicago, and it is the first of several new treatment centers the company plans to...
Field Trip Health this week...
01/27/2021
Behavioral Healthcare Executive

Advertisement

Stay in the Know

Behavioral Healthcare Executive Newsletter

Popular Articles

Ron Manderscheid, PhD
Perspectives
Social Isolation Epidemic Must Be Confronted Head-On
05/18/2023
Ron Manderscheid, PhD
With a rise in loneliness putting the nation at an increased risk of depression, anxiety, and substance use, US Surgeon General Vivek Murthy, MD, has proposed a national strategy for improving social connection.
With a rise in loneliness putting the nation at an increased risk of depression, anxiety, and substance use, US Surgeon General Vivek Murthy, MD, has proposed a national strategy for improving social connection.
With a rise in loneliness...
05/18/2023
Behavioral Healthcare Executive
Rosalynn Carter: Stigma has `a long way to go`
01/23/2013
Former First Lady reflects 40-plus years of fighting stigma, advocating for those with mental illnesses, in this exclusive interview.
Former First Lady reflects 40-plus years of fighting stigma, advocating for those with mental illnesses, in this exclusive interview.
Former First Lady reflects...
01/23/2013
Behavioral Healthcare Executive
News
Rogers to be Honored for Leadership in Combating Opioid Epidemic
10/22/2019
U.S. Rep. Hal Rogers, the Kentucky Congressman who has led various federal initiatives to combat the opioid epidemic, will be honored on Wednesday in Washington, D.C., by Mothers Against Prescription Drug Abuse (MAPDA) with the organization’s...
U.S. Rep. Hal Rogers, the Kentucky Congressman who has led various federal initiatives to combat the opioid epidemic, will be honored on Wednesday in Washington, D.C., by Mothers Against Prescription Drug Abuse (MAPDA) with the organization’s...
U.S. Rep. Hal Rogers, the...
10/22/2019
Behavioral Healthcare Executive
News
AMA Releases Full Language of New CPT Code for Psychedelic Therapies
07/06/2023
Tom Valentino, Digital Managing Editor
The new Current Procedural Terminology III code for continuous in-person monitoring and intervention during psychedelic medication therapy will go into effect on January 1, 2024.
The new Current Procedural Terminology III code for continuous in-person monitoring and intervention during psychedelic medication therapy will go into effect on January 1, 2024.
The new Current Procedural...
07/06/2023
Behavioral Healthcare Executive
News
Americans support coverage of all levels of care for mental and addictive disorders, survey says
12/18/2012
A national study conducted by Public Opinion Strategies for the National Association of Psychiatric Health Systems (NAPHS) says that 93% of Americans agree that these types of services should be covered.
A national study conducted by Public Opinion Strategies for the National Association of Psychiatric Health Systems (NAPHS) says that 93% of Americans agree that these types of services should be covered.
A national study conducted by...
12/18/2012
Behavioral Healthcare Executive

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement